The DOI matches its Crossref record; 32 of the 44 references it cites were found in a registry or an index, and 12 are not checked yet; none of the 37 sources its claims cite is checked for support yet.
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
Open accessAbstract
Maintenance of telomere length and function is critical for the efficient proliferation of eukaryotic cells. Here, we examine the interactions between telomere dysfunction and p53 in cells and organs of telomerase-deficient mice. Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis. Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis. Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process. Together, these studies establish a key role for p53 in the cellular response to telomere dysfunction in both normal and neoplastic cells, question the significance of crisis as a tumor suppressor mechanism, and identify a biologically relevant stage of advanced crisis, termed genetic catastrophe.
Checked 2026-10-06 · 12 references not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In telomerase-deficient (mTR−/−) mice, critically short telomeres activate p53, and deleting p53 rescues the resulting apoptosis and cell-cycle arrest — but only during early "crisis." Loss of telomere function and p53 deficiency cooperate to initiate transformation, while telomerase reconstitution mainly benefits later stages of tumorigenesis.
Key findings
- Critical telomere shortening activates p53: p53 protein was detectable in G6 mTR−/− testis but not in mTR+/+ or G6 mTR−/− p53−/− littermates; >80% of G4 and G6 MEFs stained positive for p53 at passage 6 versus 21% of mTR+/+ MEFs. p21CIP1/WAF1 rose 3- to 4-fold in G6 versus G2 mTR−/− p53+/+ MEFs, and p53-dependent CAT reporter activity increased ~2-fold.
- p53 loss rescued telomere-dysfunction phenotypes early but not late: 15% of G4–G6 mTR−/− mice (86/565) were p53−/− versus 26% of G7–G8 mice (24/91) (p = 0.015); all G5 mTR−/− p53−/− testes had normal histology, but 3 of 7 G6 and all five G7–G8 samples showed germ cell depletion. G6 mTR−/− p53−/− MEFs showed a 3-fold increase in chromosome fusions (1.65, SD 2.59 vs 0.42, SD 0.71 per metaphase; p = 0.012), with no change in telomere length (75% reduction regardless of p53 status).
- Telomere dysfunction cooperated with p53 deficiency to initiate transformation: adding mTR suppressed Myc/RAS focus formation in G6 mTR−/− p53−/− MEFs, but mTR-transfected foci had higher subcloning efficiency (23/26, 89%) than vector foci (19/32, 59%; p = 0.018). Tumor formation in SCID mice was similar between groups.
- The authors propose dividing crisis into p53-dependent "early crisis" and p53-independent "genetic catastrophe," questioning crisis as a tumor suppressor mechanism.
Methods
- Mouse genetics: mTR+/− mice crossed with p53+/− mice to generate successive generations (G1–G8) of mTR−/− animals with p53+/+, +/−, and −/− genotypes in a mixed WW6/C57BL/6 background; p53 status maintained heterozygous during matings.
- Cellular/organ assays: immunoblotting and immunohistochemistry for p53 and p21, pG13CAT reporter assays, testis histology with TUNEL, BrdU/propidium iodide FACS cell-cycle profiles, flow FISH telomere length, and metaphase spreads for chromosome fusions.
- Transformation assays: Myc/RAS cotransfection of early-passage MEFs with empty vector or an mTR genomic fragment, scoring focus formation, subcloning efficiency, and tumor formation after subcutaneous injection into SCID mice.
Limitations
- Stated: the mechanisms by which tumorigenic potential is maintained in late stages of tumorigenesis despite telomere dysfunction "remain to be determined"; whether loss of TRF2 binding, short telomeres, or fusion-bridge-breakage cycles mediate the p53 induction described also remains undetermined.
- Evident from the text: the G7–G8 genotype comparison rests on small numbers (24 of 91 mice), and all mice are in a mixed genetic background, which the authors note required cousin mating to avoid substrains.
- Evident from the text: the transformation data are from cultured MEFs and SCID xenografts, and tumor weights/efficiency between mTR and vector lines were not significantly different, so the in vivo relevance of the initiation advantage is inferred rather than directly demonstrated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
40 Own interpretation · 39 Own result · 22 Not checked yet · 6 Own method · 4 No basis given
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This activity was strictly dependent upon p53, since p53−/− and G6 mTR−/− p53−/− MEF cultures showed only background levels of CAT activity.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that p53 mediates the adverse effects of critically shortened telomeres.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 3A, DNA content analyses of G6 mTR−/− p53+/+ MEFs revealed a profile consistent with a biphasic block as evidenced by marked accumulation of cells in G1 and G2/M phases.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Indeed, analysis of metaphase spreads derived from G6 mTR−/− p53+/+ MEFs showed a rate of 0.42 (SD 0.71) chromosomal fusions per metaphase, a rate consistent with previous studies (Figure 3D) (Blasco et al. 1997; Greenberg et al. 1999; Rudolph et al. 1999”
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, p53-independent cell death becomes a more consistent feature in G7 and G8, since all of the five G7–G8 mTR−/− p53−/− testis samples showed significant germ cell depletion microscopically (Figure 2D).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, a relative increase in p53−/− mice was evident in G7 and G8 mTR−/− background (24% and 38%, respectively).”
plaincorrelationaln = 91 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gross testis size was consistently rescued to near normal in G6 mTR−/− p53−/− mice compared to G6 mTR−/− p53+/+ littermates (see Figure 2A for representative comparison).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, loss of telomere function and p53 deficiency can cooperate to enhance transformation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 36
- The quote only partly states this claim. 1
- Probably not a substantial claim. 16
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, mTR+/+ p53+/+ MEF cultures demonstrated 35% of cells in S phase and only 13% in G2/M.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR+/+ testis, p53 status did not affect testicular volume or significantly alter the cytoarchitecture of seminiferous tubules (Figure 2A and Figure 2B).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas only 21% of the mTR+/+ MEFs at passage 6 stained positive for p53, more than 80% of MEFs derived from G4 and G6 exhibited strong immunoreactivity to p53 (Figure 1B, compare [a] with [b] and [c]).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In male germ cells and lymphocytes, telomere loss elicits a strong apoptotic response, whereas MEFs experience a potent biphasic cell cycle block.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas all G5 mTR−/− p53−/− testes exhibited normal histology, 3 of 7 G6 mTR−/− p53−/− samples still showed varying degrees of pathology (Table 1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Accordingly, BrdU incorporation assay showed that 36% of the G6 mTR−/− p53+/+ cells were in G1 phase, 3% were in S phase, and 40% were in G2/M (Figure 3A, top panel).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoprecipitation and Western blot analysis readily detected p53 in lysates from G6 mTR−/− testis, but not in lysates derived from age-matched mTR+/+ testis or from G6 mTR−/− p53−/− littermate controls (Figure 1A).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This induction of p53 coincides with the dramatic increase in apoptosis (as assessed by TUNEL) and decreased cellularity in the G6 mTR−/− testis (Lee et al. 1998”
What the sources say
- Not checked yetcites Lee et al. 1998 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Significantly, loss of p53 rescues the cell cycle arrest in MEFs and the apoptotic elimination of male germ cells.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of p53 abrogated this block.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significantly, 15% of the G4–G6 mTR−/− mice (86 out of 565 mice) were p53−/− compared to 26% of the G7–G8 mTR−/− mice (24 of 91 mice) (p = 0.015 by Fisher’s two-sided t test) (Figure 1E).”
plaincorrelationaln = 565 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By comparison, G6 mTR−/− p53−/− MEFs exhibited 1.65 (SD 2.59) fusions per metaphase, a 3-fold increase (p = 0.012).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the case of MEFs, this arrest occurs in concert with the stabilization and activation of the p53 protein, evident in p53-dependent reporter assays and activation of p21CIP1/WAF1.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar differences were observed in low-density seeding experiments (data not shown).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In human cells, a critical telomere length is eventually reached that induces cellular senescence, thus limiting the replicative capacity of cultured cells at the Hayflick limit (Hayflick and Moorhead 1961”
What the sources say
- Not checked yetcites Hayflick and Moorhead 1961 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“In primary cells deficient for Rb and p53, continued cellular growth beyond the Hayflick limit results in severe telomere shortening, marked genetic instability, and massive cell death—a period referred to as crisis (Counter et al. 1992”
What the sources say
- Not checked yetcites Counter et al. 1992 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Ectopically expressed hTERT maintains telomere length and allows unlimited growth (Bodnar et al. 1998; Counter et al. 1998; Vaziri and Benchimol 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The notion that telomere function may indeed be required for immortalization is supported by the frequent activation of telomerase or ALT in human cancers (Kim et al. 1994; Bryan et al. 1995”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The telomere signal that activates this senescent program operates through the RB and p53 pathways, since cell division beyond the Hayflick limit can occur after antisense neutralization (Hara et al. 1991”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Telomerase is comprised of essential catalytic (telomerase reverse transcriptase [TERT]) and RNA components (telomerase RNA [TR]) (reviewed in Greider 1998”
What the sources say
- Not checked yetcites Greider 1998 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Strikingly, as mTR−/− mice advance with age and generation, an increase in cancer incidence is observed presumably due to increased genetic instability caused by telomere shortening, repeated chromosomal fusion-bridge-breakage cycles, and chromosomal loss (Rudolph et al. 1999”
What the sources say
- Not checked yetcites Rudolph et al. 1999 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Due to the very long telomeres of Mus musculus, critical reduction in telomere length and chromosomal instability is only seen following extensive passage of mTR−/− cells (Niida et al. 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The RNA subunit provides the template for telomere repeat synthesis (Greider and Blackburn 1989; Yu et al. 1990”
What the sources say
- Not checked yetcites Greider and Blackburn 1989
- Not checked yetcites Yu et al. 1990
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“although immortalization of some epithelial cells requires not only TERT expression but also compromise of the RB pathway (Kiyono et al. 1998”
What the sources say
- Not checked yetcites Kiyono et al. 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although loss of telomere and p53 function facilitates initiation of transformation, the reconstitution of telomerase activity greatly improved the capacity of transformed foci to yield immortal cultures.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because G2 mTR−/− and G6 mTR−/− MEFs both lack telomerase activity, we conclude that telomere shortening or associated chromosome fusions and breakage rather than telomerase deficiency per se signals to p53 and accounts for p21CIP1/WAF1 induction.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the rampant genetic instability of the G7 and G8 mTR−/− p53−/− cells is associated with loss of cell viability despite p53 deficiency, implying that advanced genomic catastrophe gives way to a p53-independent process.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results indicate that telomere dyfunction acts synergistically with p53 deficiency to initiate malignant transformation, presumably by enhancing genetic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continued proliferation in the absence of the p53 checkpoint may lead to an increased loss of telomere sequences and therefore account for the increased frequency of chromosome fusions.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For these matings, the p53 status was maintained in the heterozygous state to avoid potential broad genomic effects arising from p53 deficiency.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ability of exogenous telomerase to reduce focus formation in p53 null cells with short dysfunctional telomeres suggests that genetic instability associated with telomere loss can serve as an engine driving initiation of transformation, but only in the absence of functional p53 (Figure 5).”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Focus formation reflects the earliest stages of oncogenic transformation.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Early crisis accounts for efficient germ cell depletion in G6 mTR−/− p53+/+, whereas the altered histology of G7 and G8 mTR−/− p53−/− testis provides experimental support for late crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these data indicate that p53 deficiency restores neither telomere length nor function in the telomerase-deficient mouse.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This mating scheme also produced p53+/+ and p53−/− littermate controls for each mTR−/− generation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Telomere shortening in mTR−/− mice results in loss of telomere function and chromosome end-to-end fusion (Blasco et al. 1997; Rudolph et al. 1999”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observation that mTR expression facilitates subcloning efficiency of Myc/RAS-transformed late-generation mTR−/− cells supports the importance of telomere maintenance mechanisms during later stages of carcinogenesis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Induction of double strand breaks in DNA by ionizing radiation or genotoxic chemotherapy leads to the rapid stabilization of p53 through phosphorylation of its N terminus (Shieh et al. 1997; Siliciano et al. 1997”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together with previous work, our data indicated that, first, during the early stages of tumorigenesis, cells suffer telomere shortening, and second, that telomerase activation is advantageous primarily in later stages of tumorigenesis.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Many human tumors that are telomerase positive still have short telomeres.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells with short telomeres and intact p53-mediated DNA damage responses may be more efficiently “culled” from the population (via apoptosis or arrest); therefore, p53 null cells may accumulate more end-to-end fusions than their p53+/+ counterparts.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Once both telomere function and p53 have been impaired, the fate of the cell is unpredictable and depends on other stochastic genetic changes.”
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This stabilization results in either cell cycle arrest via transcriptional induction of the p21CIP1/WAF1 CDK inhibitor or apoptosis (reviewed in Levine 1997”
What the sources say
- Not checked yetcites Levine 1997 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of p53 can circumvent this checkpoint, leading eventually to p53-independent apoptosis, perhaps as a consequence of uncontrolled chromosome fusion-bridge-breakage cycles and progressive genomic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, both the apoptotic response and cell cycle arrest induced by telomere dysfunction are mediated by p53.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For telomere length determination of MEFs, littermate MEF cultures were assayed simultaneously to reduce experimental variability.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“At least two independent determinations of the same cultures were performed.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Day to day variations in the linearity of the flow cytometer were controlled by the use of FITC-labeled fluorescence beads (Flow Cytometry Standards Corporation).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Three independent age-matched sets of animals were used.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR−/− INK4a−/− mice, it is likely that telomere dysfunction activates p53 via a DNA damage signaling pathway and results in growth arrest or apoptosis, limiting the efficiency of carcinogenesis”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The signals and pathways mediating the cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.
“The signals and pathways mediating these cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.”
The paper relies on this without support.
The RAD9 and MEC1 DNA damage response pathways in yeast are similar to the p53 checkpoint in mammalian cells.
“The RAD9 and MEC1 DNA damage response pathways in yeast are thought to be similar to the p53 checkpoint in mammalian cells.”
The paper relies on this without support.
The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
“The mTR−/− mouse serves as a model to study the consequences of telomere loss in vivo.”
The paper relies on this without support.
Focus formation reflects the earliest stages of oncogenic transformation.
“Focus formation is thought to reflect the earliest stages of oncogenic transformation.”
The paper relies on this without support.
Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.
“Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.”
The paper relies on this without support.
Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors emerge.
“Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors will emerge.”
The paper relies on this without support.
Many human tumors that are telomerase positive still have short telomeres.
“The fact that many human tumors that are telomerase positive still have short telomeres supports the idea that telomerase activation occurs late in tumorigenesis.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although enabling cellular growth and survival and masking degenerative phenotypes, these mTerc -/ -p53 mutant mice experience a dramatic increase in cancer incidence, shift in tumor spectrum toward epithelial cancers, and accumulation of marked chromosomal aberrations targeting cancerrelevant loci for amplification and deletion (4-6).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, p53 deficiency results in nearcomplete rescue of adverse cellular consequences associated with telomere dysfunction, including cellular growth arrest and apoptosis, progressive organ system atrophy, and physiological compromise.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Telomere dysfunction appears to engage the p53-dependent double-stranded break DNA damage pathway.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the p53 checkpoint is compromised, unchecked genomic instability caused by telomere dysfunction accelerates tumorigenesis as seen in late-generation mTerc -/ -p53 mutant mice (4, 5).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The downstream effector pathways of telomere-induced senescence are largely p53-dependent96, but there may be involvement of the retinoblastoma protein (RB) pathway in some settings97.”
From The telomere syndromes (2012) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“recent reports of the effect of the mTR deletion in different genetic backgrounds (17, 18) suggest that the role of telomerase in cancer development could be highly context dependent (19).”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [18]
In the citing paper
“By contrast, p53 inactivation alone is sufficient to avoid telomere-induced senescence and apoptosis in mice49,50.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [49]
In the citing paper
“In the absence of telomerase, continued cell division results in telomere shortening, loss of ‘capping’ function, and p53 activation12-15.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“p53 deficiency markedly attenuates the degenerative phenotypes associated with telomere dysfunction, whereas constitutively activated p53 accelerates ageing phenotypes15-18.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“Critically short telomeres induce cellular and tissue defects through checkpoint signaling pathways that converge on the p53 tumor suppressor protein, a well-known cellular stress sensor that enforces cell cycle arrest or cell death in response to diverse stimuli including activated oncogenes, DNA damage and hypoxia (69)”
From Telomeres and telomerase in cancer (2010) · cites this paper as [69]
In the citing paper
“Importantly, removal of p53 function rescued many of the cellular defects despite the presence of critically short telomeres, including growth arrest in cell culture, testicular atrophy, intestinal and germ cell apoptosis46.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [46]
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“INK4a2/2 centration of 10 mM for 3.5 hr. Cells were processed as previouslymice lack functional p19ARF, a modulator of p53 function described (Serrano et al., 1997).activated by inappropiate oncogene activation, but re- tain intact DNA damage–induced p53 activation (Kamijo MEF Transformation…”
MethodInfluentialExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citation
Cited by
Sorted by citations
Items 701–800 of 975
Sabokrouh, A., Goodarzi, M. T., Vaisi‐Raygani, A., Khatami, S., & Taghizadeh-Jahed, M. (2014) · Europe PMC (PubMed Central) · Cited by 10
TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC
Jablonowski, C. M., Gil, H. J., Pinto, E. M., Pichavaram, P., Fleming, A. M., Clay, M. R., Hu, D., Morton, C. L., Pruett‐Miller, S. M., Hansen, B. S., et al. (2022) · Cancers · doi:10.3390/cancers14071655 · Cited by 10
de Oliveira, F. M., Jamur, V. R., Merfort, L. W., Pozzo, A. R., & Mai, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-10094-5 · Cited by 10
“On the other hand, during replicative senescence, in the absence of telomerase activity, the telomeres eventually shorten, and the cell begins cell cycle arrest, at G1 phase [6].”
BackgroundTelomerase: from Aging to Human Cancers
Parsa, N. (2012) · Springer eBooks · doi:10.1007/978-94-007-4632-9_1 · Cited by 15
Potential clinical role of telomere length in human glioblastoma.
Torre, D. L., Aguennouz, M., Conti, A., Giusa, M., Raffa, G., Abbritti, R. V., Germanò, A., & Angileri, F. F. (2011) · Europe PMC (PubMed Central) · Cited by 10
Mechanisms of Gastrointestinal Malignancies
Katona, B. W., & Lynch, J. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00066-9 · Cited by 11
Zhao, B., Gao, C., Shi, D., Mao, J., Zhao, J., Guo, L., Guo, J., & Jiao, Z. (2019) · Oncology Reports · doi:10.3892/or.2019.7327 · Cited by 10
Marie-Egyptienne, D. T., Brault, M. E., Zhu, S., & Autexier, C. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.10.020 · Cited by 10
Jiang, S., Wang, Y., Gao, H., Luo, Q., Wang, D., Li, Y., Yong, Y., & Yang, X. (2019) · BioMed Research International · doi:10.1155/2019/2072635 · Cited by 10
A Mouse Model of Oral-Esophageal Carcinogenesis
Opitz, O. G., Quante, M., von Werder, A., Heeg, S., & Blum, H. E. (2004) · Oncology Research and Treatment · doi:10.1159/000082039 · Cited by 10
Analysis of Tumor Suppressor Gene-Induced Senescence
Campisi, J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-329-1:155 · Cited by 9
Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors.
Aragona, M., Buda, C. A., Panetta, S., Morelli, M., Giudice, A. L., Campagna, F., Pontoriero, A., Cascinu, S., & Torre, F. L. (2000) · Oncology Reports · doi:10.3892/or.7.5.987 · Cited by 10
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer
Nanni, S., Narducci, M., Pietra, L. D., Moretti, F., Grasselli, A., Carli, P. D., Sacchi, A., Pontecorvi, A., & Farsetti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215552 · Cited by 10
Sahm, V., Maurer, H. C., Baumeister, T., Anand, A., Strangmann, J., Schmid, R. M., Wang, T. C., & Quante, M. (2022) · Oncotarget · doi:10.18632/oncotarget.28198 · Cited by 9
“When p53, the main mediator for telomere induced senescence, was abrogated additionally to telomere dysfunction, tumor growth was enhanced [42, 43].”
BackgroundLack of telomerase reduces cancer incidence and increases lifespan of zebrafish tp53M214K mutants
Şerifoğlu, N., Lopes-Bastos, B., & Ferreira, M. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-56153-8 · Cited by 9
“However, this comes at the high cost of increased genome instability and cancer 29,30 .”
Genomic instability in�both wild-type and telomerase null MEFs
Hao, L.-Y., & Greider, C. W. (2004) · Chromosoma · doi:10.1007/s00412-004-0291-7 · Cited by 9
Self-citationPrindull, G. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.07.009 · Cited by 9
Prognostic value of leukocyte telomere length in renal cell carcinoma patients.
Chen, M., Tsai, C.-W., CHANG, W.-S., Xu, J., Xu, Y., BAU, D.-T., & Gu, J. H. (2020) · PubMed Central · Cited by 9
Hsu, W., Lin, B., Leu, J., Lo, P., Yu, H.-Y., Chen, C.-T., Tu, Y.-H., Lin, Y., & Lee, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-76797-6 · Cited by 9
Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists
Crisà, E., Boggione, P., Nicolosi, M., Mahmoud, A. M., Essa, W. A., Awikeh, B., Aspesi, A., Andorno, A., Boldorini, R. L., Dianzani, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052525 · Cited by 9
Arsenic-Induced Mutagenesis and Carcinogenesis
Maiti, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418688-0.00009-5 · Cited by 9
PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation
Ngo, H.-P., Hyatt, S., Grimstead, J. W., Jones, R. E., Hendrickson, E. A., Pepper, C. J., & Baird, D. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26499 · Cited by 9
Mollano, A. V., Martin, J. A., & Buckwalter, J. A. (2002) · Europe PMC (PubMed Central) · Cited by 9
Molekularmedizinische Grundlagen von altersspezifischen Erkrankungen
Ganten, D., & Bähr, M. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4 · Cited by 10
Cho, E., & Li, W. (2007) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20088 · Cited by 9
Replicative Senescence and Cancer
Hornsby, P. J. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-23962-6_3 · Cited by 9
Horikawa, I., Yawata, T., & Barrett, J. C. (2000) · Rejuvenation Research · doi:10.1089/rej.1.2000.3.373 · Cited by 9
asy andasyip: A new type of apoptosis-inducing gene
Qi, B., Qi, Y., Liu, Q., & Qu, X. (2001) · Chinese Science Bulletin · doi:10.1007/bf03187019 · Cited by 9
Hou, H., & Cooper, J. P. (2018) · Differentiation · doi:10.1016/j.diff.2018.01.002 · Cited by 10
Furuie, H., Arimura‐Omori, M., Hamada, N., Yanagihara, T., & Kiyohara, C. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.4.1279 · Cited by 8
“The tumor suppressor p53 (TP53), which has been shown to interact with tumor protein p53-binding protein 1 (TP53BP1), is implicated in the response to telomere shortening (Chin et al., 1999).”
BackgroundAssociation between haemorrhagic fever with renal syndrome and cancers
Yi, Y. J., Kang, M., Kim, W., Huh, K., Klingström, J., Song, J., & Jung, J. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.014 · Cited by 8
The telomere complex and the origin of the cancer stem cell
Torres-Montaner, A. (2021) · Biomarker Research · doi:10.1186/s40364-021-00339-z · Cited by 8
Kato, H., Maezawa, Y., Nishijima, D., Iwamoto, E., Takeda, J., Kanamori, T., Yamaga, M., Mishina, T., Takeda, Y., Izumi, S., et al. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.02.005 · Cited by 8
Lu, Y., Wei, B., Zhang, T., Chen, Z., & Ye, J. (2013) · Protein & Cell · doi:10.1007/s13238-013-3002-4 · Cited by 8
Intracellular efficacy of tumor‐targeting group I intron‐based trans‐splicing ribozyme
Kwon, B. S., Jeong, J. S., Won, Y.-S., Lee, C. H., Yoon, K., Jung, M. H., Kim, I., & Lee, S. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1545 · Cited by 8
Self-citationAetiology of Late Age-Related Macular Disease
Spaide, R. F. (2005) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/3-540-27272-0_7 · Cited by 8
“Production or activation of p53 encourages senescence, while inactivation of p53 can lead to rescue from senescence, with an increase in the tendency for carcinogenesis [32].”
Bernal, A., Zafon, E., Domínguez, D., Bertran, E., & Tusell, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072078 · Cited by 9
“This dual capacity depends on the genetic context where dysfunctional telomeres occur, as highlighted by their enhanced tumorigenic potential when p53 is co-deleted [17,18,61].”
Clarke, M. A., Woodhouse, S., Piterman, N., Hall, B. A., & Fisher, J. (2019) · Computational biology · doi:10.1007/978-3-030-17297-8_5 · Cited by 8
Blasco, M. A. (2001) · BioMed Research International · doi:10.1155/s1110724301000109 · Cited by 8
Treating cancer with embryonic stem cells: rationale comes from aging studies
Svetlana, V. U. (2005) · Frontiers in bioscience · doi:10.2741/1555 · Cited by 8
Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX
Wahl, G. M., Stommel, J. M., Krummel, K. A., & Wade, M. R. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_4 · Cited by 9
“, 1991; Wahl and Carr, 2001), short or abnormally structured telomeres (Chin et al., 1999; Karlseder et al., 1999), metabolic and other consequences of high level oncogene signaling (Denko et al.”
A CPC-shelterin-BTR axis regulates mitotic telomere deprotection
Romero‐Zamora, D., Rogers, S., Low, R. R. J., Page, S. G., Lane, B. J. E., Kosaka, S., Robinson, A. B., French, L., Lamm, N., Ishikawa, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57456-8 · Cited by 10
“…fi rst and is mediated by a telomere-speci fi c DDR that promotes p53-dependent proliferative arrest 4,17 . p53 compromised cells are refractory to this telomere DDR and continue cell division 17,18 until excessive telomere erosion confers end-to-end chromosome fusions and cell death at crisis 5,19 .”
Luo, Q., Wang, J., Ge, W., Li, Z., Mao, Y., Wang, C., & Zhang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28944 · Cited by 8
“Telomere dysfunction is related to several chronic inflammatory diseases, including IBD [46 – 48] [46 – 48] [46 – 48].”
BackgroundTelomere dysfunction in Tert knockout mice delays BrafV600E ‐induced melanoma development
Zhang, J., Zhang, F., Porter, K. I., Dakup, P., Wang, S., Robertson, G. P., Gaddameedhi, S., & Zhu, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34713 · Cited by 7
“36,37 Indeed, p16 Ink4a expression increased markedly in all tumors even in G0 mice (Figure 3C).”
Télomères : un Nobel pour le début de la fin
Rajpar, S., Guittat, L., & Mergny, J. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1378 · Cited by 9
Dai, W. H., & Wang, X. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.7.pe9 · Cited by 7
CHK2‐independent induction of telomere dysfunction checkpoints in stem and progenitor cells
Nalapareddy, K., Choudhury, A. R., Gompf, A., Ju, Z., Ravipati, S., Leucht, T., Lechel, A., & Rudolph, K. L. (2010) · EMBO Reports · doi:10.1038/embor.2010.83 · Cited by 6
Translating basic aging research into geriatric health care
Hamerman, D., & Zeleznik, J. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00200-x · Cited by 7
Immunohistochemical TRF1 expression in human primary intracranial tumors.
Aragona, M., DIVITIIS, O. D., Torre, D. L., Panetta, S., D’Avella, D., Pontoriero, A., Morelli, M., Torre, I. L., & Tomasello, F. F. (2001) · PubMed · Cited by 7
Manipulating mouse telomeres: models of tumorigenesis and aging
Xin, Z., & Broccoli, D. (2004) · Cytogenetic and Genome Research · doi:10.1159/000078221 · Cited by 7
“…is critical for both the apoptotic and senescent responses to dysfunctional telomeres, some of the aging-associated phenotypes in Terc–/– mice such as reduction in reproductive competence could be rescued by crossing the null p53 alleles (p53–/–) into the Terc null background (Chin et al., 1999).”
BackgroundInfluentialA unified and self-reinforcing mechanism of tumor cell immortality
Stevers, N. O., Kim, S., Yuan, J. B., Barger, C. J., Hong, C., Lenzo, O., McKinney, A., Wu, S. H., Lee, Y. J., Kwok, D. W., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2025.05.026 · Cited by 6
Muñoz‐Alarcón, A., Eriksson, J., & Langel, Ü. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0558 · Cited by 6
Nelson, W. G., Antonarakis, E. S., Carter, H. B., Marzo, A. M. D., & DeWeese, T. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00081-5 · Cited by 6
Lithium effects on stem cells - advances in stem cell application in clinical medicine
Gallicchio, V. S. (2018) · doi:10.35841/cell-science.2.1.1-11 · Cited by 6
On the significance of telomerase activity in human malignant glioma cells
Vietor, M., Winter, S., Groscurth, P., Naumann, U., & Weller, M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00726-3 · Cited by 6
Clinical applications of telomerase in cancer treatment
Faraoni, I., Bonmassar, E., & Graziani, G. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0139 · Cited by 6
Inhibition of cell growth and telomerase activity in osteosarcoma cells by DN-hTERT
Xu, T., Rao, Y., Zhu, W., & Guo, F. (2006) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-006-0532-5 · Cited by 6
Igarashi, M., Suda, T., Hara, H., Takimoto, M., Nomoto, M., Takahashi, T., Okoshi, S., Kawai, H., Mita, Y., Waguri, N., et al. (2003) · PubMed · Cited by 6
DNA Damage, Repair and Misrepair in Cancer and in Cancer Therapy
Ana, M., Ferreira, L. M. R., Joana, F., Carlos, F., & Maria, C. (2011) · InTech eBooks · doi:10.5772/23190 · Cited by 5
Targeting Telomerase in Hematologic Malignancy
Maritz, M. F., Napier, C. E., Wen, V. W., & MacKenzie, K. L. (2010) · Future Oncology · doi:10.2217/fon.10.42 · Cited by 5
“These observations are consistent with the notion that telomere length limits HSC function, as well as data that show that critically short telomeres promote genetic instability [23,135,136].”
BackgroundTumiati, M., Munne, P., Edgren, H., Eldfors, S., Hemmes, A., & Kuznetsov, S. G. (2016) · Oncogene · doi:10.1038/onc.2015.528 · Cited by 5
Telomerase reverse transcriptase mutation and the p53 pathway in T1 urinary bladder cancer
Jahnson, S., Söderkvist, P., Aljabery, F. A.-S., & Olsson, H. (2021) · British Journal of Urology · doi:10.1111/bju.15490 · Cited by 5
Khatami, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-66475-0_3 · Cited by 6
Chronowski, C., Akhanov, V., Chan, D. W., Catic, A., Finegold, M. J., & Sahin, E. (2021) · Metabolites · doi:10.3390/metabo11060394 · Cited by 5
Mouse models of testicular germ cell tumors
Carouge, D., & Joseph, H. B. (2012) · InTech eBooks · doi:10.5772/38921 · Cited by 5
“Furthermore, www.intechopen.com Mouse Models of Testicular Germ Cell Tumors 87 telomerase dysfunction activates TRP53-dependent apoptosis (Chin et al., 1999).”
BackgroundExploring cellular senescence as a tumor suppressor mechanism
Carnero, A., Blanco‐Aparicio, C., Blanco, F., Castro, M. E., Guijarro, M. V., Fominaya, J. M., Link, W., Martínez, J. F., Moneo, V., Renner, O., et al. (2003) · Revista de Oncología · doi:10.1007/bf02711481 · Cited by 6
Cellular Senescence as a Target in Cancer Control
Carnero, A. (2007) · Current Cancer Therapy Reviews · doi:10.2174/157339407780126629 · Cited by 5
Development of telomerase inhibitors
Rowley, P. T. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.12.1815 · Cited by 5
Roberts, A. R., Huang, E., Jones, L., Daxinger, L., Chong, S., & Whitelaw, E. (2013) · Chromosoma · doi:10.1007/s00412-013-0427-8 · Cited by 5
“…important in telomere-related cellular senescence in human cells, and increased levels of p53 protein has been reported in late generation Terc null and in late generation Tert null mouse cells with short telomeres (Chin et al. 1999; Herbig et al. 2004; Zglinicki et al. 2005; Nakamura et al. 2008).”
Tumour suppression: something for nothing?
de Stanchina, E., & Lowe, S. W. (2002) · Nature Cell Biology · doi:10.1038/ncb1202-e275 · Cited by 5
Hurria, A., Muss, H. B., & Cohen, H. J. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm074 · Cited by 5
Chaux, F., Agier, N., Garrido, C., Fischer, G., Eberhard, S., & Xu, Z. (2023) · Genome Research · doi:10.1101/gr.278043.123 · Cited by 5
Propagation of Homalodisca coagulata virus-01 via Homalodisca vitripennis Cell Culture
Biesbrock, A. M., Powell, C. M., Hunter, W. B., & Bextine, B. R. (2014) · Journal of Visualized Experiments · doi:10.3791/51953 · Cited by 4
Zole, E., Elferts, D., Ķimsis, J., Krūmiņa, A., Narels, K., Pole, I., Ranka, R., & Pliss, L. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.01.002 · Cited by 3
Scahill, C. M., Digby, Z., Sealy, I. M., White, R. J., Wali, N., Collins, J. E., Stemple, D. L., & Busch‐Nentwich, E. M. (2017) · Wellcome Open Research · doi:10.12688/wellcomeopenres.12530.2 · Cited by 7
RGL2 as an age-dependent factor regulates colon cancer progression
Cheng, Q., Wu, Y., Xia, H., & Song, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.006 · Cited by 4
“Loss of p53 function could restore many cellular defects caused by telomere dysfunction, including growth arrest and cellular apoptosis [11].”
Telomeres and Reproductive Aging
Aydos, S. (2012) · InTech eBooks · doi:10.5772/38854 · Cited by 4
“Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?”
BackgroundRobinson, M. O. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4199-8_12 · Cited by 4
Blasco, M. A. (2001) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(01)08008-7 · Cited by 4
Weak Telomerase Activity in Malignant Cells in Metastatic Serous Effusions
Zendehrokh, N., Franzen, L., & Dejmek, A. (2007) · Acta Cytologica · doi:10.1159/000325756 · Cited by 4
Lynch, J. P., & Rustgi, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00080-4 · Cited by 4
Ferrara, N., Corbi, G., Scarpa, D., Rengo, G., Longobardi, G., Mazzella, F., Cacciatore, F., Rengo, F., & Terme, T. (2005) · Cited by 4
Woo, S. R., Park, J.-E., Juhn, K.-M., Ju, Y.-J., Jeong, J., Kang, C.-M., Yun, H. J., Yun, M. Y., Shin, H.-J., Joo, H.-Y., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.086 · Cited by 4
The Rap1p-Telomere Complex Does Not Determine the Replicative Capacity of Telomerase-Deficient Yeast
Smolikov, S., & Krauskopf, A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8729-8739.2003 · Cited by 4
“Progressive shortening of telomeres in the absence of telomerase results in the generation of chromosome end-to-end fusions in late generation mTR/ mice and in cell cycle arrest and p53-mediated apoptosis (5, 9 , 25, 28, 32).”
BackgroundJu, Y.-J., Park, J. Y., Juhn, K. M., Jeong, J., Yun, M., Park, M. J., Park, G. H., Choi, K., Cho, M., Wong, K., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.4.753 · Cited by 4
Extracting Extra-Telomeric Phenotypes from Telomerase Mouse Models
Sung, Y. H., Ali, M., & Lee, H. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2014.55.1.1 · Cited by 4
Telomere elongation in the gut extends zebrafish lifespanPreprint
Maï, M. E., Guigonis, J., Pourchet, T., Kang, D., Yue, J., & Ferreira, M. G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.10.475664 · Cited by 4
Zole, E., Baumanis, E., Freimane, L., Dāle, R., Leiše, A., Lietuvietis, V., & Ranka, R. (2024) · Biomedicines · doi:10.3390/biomedicines12102349 · Cited by 3
“…DNA instability, Biomedicines 2024 , 12 , 2349 2 of 15 suppress PGC-1 α / β (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha and beta) action via the p53 transcription factor, causing increased p53 activity and high levels of apoptosis in which mitochondria are involved [2–6].”
Backgroundp53, longevity assurance and longevity suppression
Donehower, L. A. (2006) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2006.02.001 · Cited by 3
The Anti-Elixir Triad: Non-Synced Circadian Rhythm, Gut Dysbiosis, and Telomeric Damage
Mani, A. K., Parvathi, V. D., & Sumitha, R. (2024) · Medical Principles and Practice · doi:10.1159/000542557 · Cited by 3
“Some cells delay senescence and continue to proliferate by acquiring genetic mutations in p53 and other checkpoint proteins [63].”
The absence of telomerase leads to immune response and tumor regression in zebrafish melanoma
Lopes-Bastos, B., Nabais, J., Ferreira, T., Allavena, G., Maï, M. E., Bird, M., Targen, S., Tattini, L., Kang, D., Yue, J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115035 · Cited by 3
Long telomeres cooperate with p53, MDM 2, and p21 polymorphisms to raise pediatric solid tumor risk
Borbora, D., Dutta, H. K., Devi, K. R., Mahanta, J., Medhi, P., & Narain, K. (2019) · Pediatrics International · doi:10.1111/ped.13915 · Cited by 3
Arsenic-induced mutagenesis and carcinogenesis: A possible mechanism
Maiti, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89847-8.00016-x · Cited by 3
Irradiation‐induced telomerase activity and the risk of lung cancer
Chen, M., Gu, J. H., Xing, J., Spitz, M. R., & Wu, X. (2007) · Cancer · doi:10.1002/cncr.22493 · Cited by 3
Falchetti, M. L., Pallini, R., & Levi, A. (2004) · American Journal of Cancer · doi:10.2165/00024669-200403010-00001 · Cited by 4
Telomere Structural Dynamics in Genome Integrity Control and Carcinogenesis
Greenberg, R. A., & Rudolph, K. L. (2006) · Springer eBooks · doi:10.1007/1-4020-3764-3_11 · Cited by 3
Shingu, T., Jaskelioff, M., Yuan, L., Ding, Z., Protopopov, A. I., Kost‐Alimova, M., & HU, J. L. (2015) · Journal of Visualized Experiments · doi:10.3791/52599 · Cited by 4
Allen, T. C. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_14 · Cited by 3
Aging or tumor: the crosstalk between telomerase and p53
Zhang, X., Tang, W., & Luo, Y. (2009) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2009.00451 · Cited by 3
Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis
El‐Serag, H. B., Lechel, A., & Rudolph, K. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00010-3 · Cited by 3
Metadata
- Authors
- Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Quest Diagnostics (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- DePinho, Ronald A
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 97
- Issue
- 4
- Pages
- 527-538
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2027779909
- Cited by
- 979
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 18 · 2023: 21 · 2022: 15 · 2021: 22 · 2020: 15 · 2019: 26 · 2018: 24 · 2017: 23 · 2016: 32 · 2015: 34 · 2014: 23 · 2013: 40 · 2012: 51
- FWCI
- 36.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hd028317-05, 5r01hd034880-04, 5k08ar002104-04)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR02104-01)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD34880, R01 HD28317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- p53, telomere dysfunction, telomere shortening, telomerase deficiency, telomere crisis, carcinogenesis, genomic instability, tumor suppression, apoptosis, growth arrest, telomere length
- MeSH terms
- Animals, Male, Mice, Inbred C57BL, Neoplasms, Phenotype, Spermatozoa, Testis, Tumor Suppressor Protein p53, Telomere, Apoptosis, Telomerase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
